Jean-Paul and Martine Clozel, founders of Swiss biotech company Actelion, which has been sold to J&J, are starting over again. The husband and wife team is embarking on the creation of a new global biotech player—armed with nearly $1 billion in capital, a deep-pocketed partner in J&J and soon, a stock listing in Zurich.
from WSJ.com: US Business http://ift.tt/2mOS3xv
via IFTTT
No comments:
Post a Comment